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Abstract
Background: Systemic lupus erythematosus (SLE) is an autoimmune disease with various clinical manifestations
involving multiple organ systems. Neuropsychiatric manifestations of SLE have been associated with increased
morbidity and mortality, thus it is important to recognize and diagnose the disease entity and treat early. When
neuropsychiatric symptoms are involved, typically there are many other systemic features to aid in the diagnosis of
SLE. Many autoantibodies have been discovered and are used to help diagnose SLE. The antibody present in most
cases of pediatric SLE, as well as in many other rheumatic diseases, is the nonspecific antinuclear antibody (ANA).
The ANA is a commonly used screening tool by primary care physicians when evaluating a patient with a possible
rheumatic disorder. However, a small subset of SLE patients, 1–5%, present with a negative ANA, and it is important
to keep SLE on the differential diagnosis in specific instances when a thorough infectious, metabolic and neurological
workup has been completed and proven to be inconclusive.
Case presentation: This case involves a Hispanic adolescent female with a negative ANA who presented with diffuse
cerebral edema secondary to leukoencephalopathy due to SLE with central nervous system involvement. She was
normotensive on presentation and relatively symptom free aside from headache. She had an extensive workup while
inpatient involving metabolic, infectious disease, rheumatology, and neurology prior to obtaining the diagnosis of SLE.
She was treated with cyclophosphamide and rituximab with appropriate disease response.
Conclusions: A review of the literature revealed 12 cases with SLE presenting with or developing diffuse cerebral
edema and/or leukoencephalopathy. Our patient’s case differs in that she was also ANA negative despite other
autoantibody positivity. While she did have low complements and transient leukopenia, she did not present with other
signs of organ involvement, which made the diagnosis of SLE with neuropsychiatric involvement quite challenging. We
discuss the importance of keeping SLE on the differential diagnosis despite a negative ANA in complex cases after
thorough workup has been unrevealing, and to consider initial screening with not only the ANA but also dsDNA and
complements to avoid missed diagnoses.
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Background
Systemic lupus erythematosus (SLE) is a chronic inflam-
matory autoimmune disease characterized by multisystem
clinical manifestations and associated autoantibodies,
most commonly an antinuclear antibody (ANA) which is
present in up to 95–99% of cases of pediatric SLE. Neuro-
psychiatric involvement in SLE (NPSLE) includes both the
central and peripheral nervous system manifestations such
as stroke, seizures, myelopathy, chorea, and psychosis, and
more subtle findings such as mood disorders, cognitive
impairment, and headaches [1–5]. Currently, there are 19
NPSLE syndromes as defined by the American College of
Rheumatology [4, 6]. The prevalence of neuropsychiatric
manifestations in various cohorts ranges from as low as
20% to as high as 95% [1, 3, 4]. In 25% of pediatric patients
with SLE-related CNS disease, the initial symptom will be
at presentation, and approximately 70% of these children
will have CNS manifestations within the first year of diag-
nosis of SLE [7]. Neuropsychiatric lupus (NPSLE) has
been associated with increased morbidity and mortality,
thus is it extremely important to recognize and treat early
if present. The most frequent NPSLE manifestations are
headaches, psychiatric manifestations (including mood
disorders, psychosis, cognitive dysfunction, and acute con-
fusional state), cerebrovascular disease and seizures [4–7].
We present a case of pediatric SLE with primarily
neuropsychiatric symptoms manifesting as cerebral
edema secondary to acute leukoencephalopathy. Cere-
bral edema and leukoencephalopathy are rare reports as
manifestations of NPSLE in the literature. Many of these
patients already carried a diagnosis of SLE, previously
had manifestations of NPSLE, and/or had other systemic
symptoms related to their disease (Table 1). Further-
more, many of these patients were ANA-positive, which
made this case especially challenging as our patient was
ANA negative.
Case presentation
A 13-year old previously healthy Hispanic female pre-
sented with 1 week of nighttime fevers (Tmax 38.8 de-
grees Celsius orally), 3–4 days of occipital headache with
blurry vision, and 1 day of neck pain. Initial vital signs
were normal, including her blood pressure. She was
afebrile and awake, alert, and oriented. Her physical
exam was significant for grade IV papilledema on oph-
thalmologic exam (of note, papilledema is graded on a
scale of I-V, V being most severe; Grade IV is character-
ized by loss of major vessels on the optic disc on exam-
ination). She otherwise had a normal neurologic exam,
without meningeal signs. All other systems were normal.
Her initial differential was most concerning for infec-
tious, metabolic or neurologic causes. Initial laboratory
studies showed leukopenia with a white blood cell count
of 3.9 k/cubic mm (normal value 5–10 k/cubic mm),
normocytic, normochromic anemia (Hgb 10.4), and nor-
mal platelet count. Leukopenia was noted on 2 occasions
but was not sustained and resolved prior to treatment.
Her erythrocyte sedimentation rate (ESR) and C-
Reactive protein (CRP) were normal (see Table 2). Her
urinalysis was without proteinuria or hematuria. She had
normal renal function, electrolytes, toxicology screening,
thyroid studies, folate, and vitamin B12 levels. Initial
head CT showed diffuse cerebral swelling without her-
niation. Follow up brain MRI/MRA with and without
contrast showed “symmetric diffuse T2 hyperintensity
on the white matter of both cerebral hemispheres, brain-
stem, corpus callosum and cerebellar white matter with
mild cerebellar tonsillar ectopia and no mass or midline
shift”. This was consistent with diffuse brain swelling
secondary to acute leukoencephalopathy. Brain MRA
without contrast was without abnormalities. Due to se-
verity of her cerebral edema, a lumbar puncture was not
pursued. Despite her imaging, she was very well appear-
ing and only complaining of occasional headache.
During her hospitalization, multiple subspecialty ser-
vices were involved in her care including neurosurgery,
neurology, genetics, metabolism, infectious disease, oph-
thalmology, and rheumatology. Infectious studies were
significant for positive Ebstein-Barr Virus (EBV) Nuclear
Antigen IgG, Early Antigen IgG, Viral Capsid Antigen
IgG and negative Viral Capsid Antigen IgM, positive
Cytomegalovirus (CMV) IgG and IgM, and positive
Mycoplasma IgG and IgM. Immunofluorescent antibody
testing for mycoplasma pneumoniae IgM was negative.
Arbovirus panel testing (which includes STL Encephal-
itis virus, California encephalitis virus, eastern equine
virus, western equine virus) was sent twice and was in-
conclusive on both occasions due to specimen producing
a “non-specific fluorescence”. Serum CMV PCR, EBV
PCR, herpes simplex (HSV) virus type 1 and 2, crypto-
coccus blood antigen, human Immunodeficiency virus
(HIV) 1 and 2 antibody and antigen, influenza A/B,
adenovirus, parainfluenza 1–4, chlamydia pneumoniae,
bocavirus, coronavirus, respiratory syncytial virus (RSV)
A/B, rhinovirus/enterovirus, metapneumovirus, Lyme
disease serologies, Brucella IgM/IgG, and West Nile
IgM/IgG were all negative/unremarkable. TB spot test-
ing (blood test based on IFN-gamma responses to Myco-
bacterium tuberculosis-specific antigens) was negative.
An extensive metabolic workup was completed and re-
sults were normal, including serum amino acids, urine
organic acids, lactate, pyruvate, very long chain fatty
acids, lysosomal panel, carnitine, homocysteine, and CK.
An MR spectroscopy was completed which showed “no
significant abnormal elevated lactate peaks in the white
matter basal ganglia”, which does not support a meta-
bolic disorder. The MR spectroscopy did comment on
“elevation of the glutamine/glutamate complex in short
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echo MRS in both the left frontal lobe and right basal
ganglia” which can be seen with urea cycle disorders but
typically in the more subacute/acute phase. Upon discus-
sion with our metabolic team, her lab workup and im-
aging did not support a urea cycle disorder or other
metabolic disorder. Neurology workup was limited due
to severity of her cerebral edema and inability to obtain
CSF studies.
She was managed medically for her cerebral edema
with sodium supplementation for therapeutic hyperna-
tremia and acetazolamide. She remained afebrile until
day 4 of her hospitalization, however on hospital days 5,
6, and 7 she developed fevers. At this time, our Infec-
tious Disease team initiated doxycycline for presumed
mycoplasma infection due to positive IgG and IgM
mycoplasma titers.
Throughout her hospitalization, she remained rela-
tively normotensive (SBP/DBP: 91–122/52–83). She did
have occasional blood pressure readings that were above
her 95%ile but less than SBP 130. However, these read-
ings were never persistent and did not require any medi-
cation. On day 7 of her hospital stay, she had acute
deterioration and became unresponsive and obtunded,
requiring emergent intubation. Her blood pressure at
this time was slightly elevated at 142/95. A repeat head
CT done at that time showed stable cerebral edema
without new changes or herniation. EEG was negative
for seizure activity. She was extubated to room air within
24 h and remained stable throughout the remainder of
her hospitalization. Her blood pressure on day 8 of
hospitalization was 135/86–139/86, after which she
returned to being normotensive.
Rheumatology was consulted on day 8 of her admission
for concern for CNS vasculitis or other autoimmune eti-
ologies. She had an initial rheumatologic workup (see
Table 2) that included ANA of < 1:40 by immunofluores-
cence (IF), but elevated anti-dsDNA (82.2), low C3 [19]
and low C4 [2]. Antiphospholipid antibodies were signifi-
cant for beta 2-glycoprotein IgA 7.0 (reference range being
< 7.0), with beta-2 glycoprotein IgG and IgM negative,
anti-cardiolipin antibodies negative, and lupus anticoagu-
lant negative. The hypocomplementemia and positive
anti-dsDNA antibody prompted further evaluation, specif-
ically for SLE. Additional lab testing revealed positive
Smith (> 8), SSA (> 8), SSB (1.2, reference range < 1.0),
RNP (2.1, reference range < 1.0), Ribosomal P (> 8) and
neuronal (> 400, reference range 0–54) antibodies. ANA
was repeated and again noted to be < 1:40 by IF (Refer-
ence Table 2 for rheumatologic workup). She was ultim-
ately diagnosed with SLE with CNS involvement. At this
point in her disease process she had no other apparent
organ involvement or other SLE features.
Table 2 Rheumatologic lab results and normal values
Lab Test Patient Value Normal Value
CRP < 0.5 mg/dL < 1.0 mg/dL
ESR 9 mm/hr 0–20mm/hr
Complements (C3, C4) C3: 12 mg/dL
C4: 2 mg/dL
C3: 65–180mg/dL
C4: 13–52 mg/dL
beta 2-glycoprotein IgA QN 7.0 Units/mL 0.0–6.9 Units/mL
beta-2 glycoprotein IgG QN 5.8 Units/mL 0.0–6.9 Units/mL
beta-2 glycoprotein IgM QN 1.1 Units/mL 0.0–6.9 Units/mL
anti-cardiolipin antibody IgA 5.9 APL Units > 22 APL Units may be clinically significant
anti-cardiolipin antibody IgG 6.5 GPL Units 0.0–9.9 GPL Units
anti-cardiolipin antibody IgM 4.8 MPL Units 0.0–9.9 MPL Units
lupus anticoagulant 31.6 s 24.3–42.6 s
ANA < 1:40 < 1:80
Anti-dsDNA (on presentation) 82.2 IU/mL 0.0–9.9 IU/mL
Anti-dsDNA (13 months after treatment) 8.6 IU/mL 0.0–9.9 IU/mL
Anti-Smith > 8.0 > 1.0 Test Value Positive
Anti-SSA EIA > 8.0 > 1.0 Test Value Positive
Anti-SSB EIA 1.2 > 1.0 Test Value Positive
Anti-RNP 2.1 > 1.0 Test Value Positive
Anti-Smith/RNP EIA 5.7 > 1.0 Test Value Positive
Anti-Ribosomal P EIA > 8.0 > 1.0 Test Value Positive
Anti-Neuronal serum Ab > 400 Units 0–54 Units
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She initiated treatment for SLE and received 5 days of
IV methylprednisolone (1 g) in addition to IV cyclophos-
phamide (initial dose 500mg/m2) and IV Rituximab
(500 mg/m2). Repeat MRI prior to discharge showed
stable cerebral edema and leukoencephalopathy (Fig. 1).
Her headaches subjectively improved with therapy, and
repeat ophthalmologic exam showed improvement of
papilledema from grade IV to grade II-III by time of dis-
charge. She was discharged home on day 19 of
hospitalization on prednisone 60mg daily, hydroxychlor-
oquine, and acetazolamide, with the outpatient manage-
ment plan of second Rituximab infusion and monthly
cyclophosphamide infusions and with IV solumedrol
pulse dose therapy.
Figure 1 formal read: “Symmetric and confluent T2 in-
tensity within white matter. Involvement of the corpus
callosum splenium, internal and external capsule, brain-
stem at the dorsal tegmental tracts of the pons. Moder-
ate degree of gray matter involvement at the anterior
temporal lobe on the right and posterior left frontal lobe
around the area of the precentral gyrus. No abnormal
areas of reduced diffusion”. This was our patient’s result-
ant MRI after completing treatment prior to discharge.
Discussion
This case report describes a pediatric patient with a new
diagnosis of ANA-negative SLE with the initial findings
of diffuse cerebral edema and acute leukoencephalopa-
thy on imaging, characterized symptomatically only by
headache, blurry vision and Grade IV papilledema on
examination. Her fevers were thought to be due to active
lupus as opposed to a CNS manifestation, largely be-
cause her cerebral involvement was quite diffuse as op-
posed to focused near the hypothalamus, where
temperature regulation takes place. Hypothetically, if the
fevers were secondary to CNS involvement she would
have spiked fevers much more frequently given the se-
verity of her CNS involvement on imaging. Instead, she
spiked fevers intermittently. According to the literature,
the finding of diffuse cerebral edema with or without
leukoencephalopathy in NPSLE is extremely rare, and if
present, develops later in the disease course and typically
with other systemic signs of the disease. SLE patients
with concern for neuropsychiatric involvement most
commonly present with headaches, seizures, stroke, de-
pression, and/or cognitive dysfunction as the sign of
central neurologic involvement [4–7]. There have been
case reports of patients with isolated intracranial hyper-
tension as the only sign of neuropsychiatric lupus, and a
few with intracranial hypertension with associated leu-
koencephalopathy (see Table 1), but we were unable to
find an instance of a patient with isolated diffuse leu-
koencephalopathy as the presenting sign of lupus upon
initial diagnosis. Many other patients described had
other systemic signs/symptoms and already carried the
diagnosis of SLE. Furthermore, most cases in the litera-
ture had a positive ANA in their workup to further assist
in the diagnosis of SLE. Additional risk factors associ-
ated with development or worsening of NPSLE include
generalized SLE activity or damage, history of previous
or concurrent other major NPSLE, and antiphospholipid
antibodies [3, 4]. Our patient did not have any of these
risk factors.
As shown in Table 1, most of the case reports
reviewed described intracranial hypertension with or
without leukoencephalopathy [8–18]. Of the three cases
that were children (ages, 7y, 11y, and 14y), all had a
positive ANA, and one out of the three pediatric cases
had a previous diagnosis of SLE. All cases reported mul-
tiple other clinical manifestations of SLE in addition to
CNS involvement, unlike our patient. Imaging findings
reported were consistent in showing diffuse hyperinten-
sities on MRI suggestive of leukoencephalopathy, similar
to our patient. Patient outcome across case reports were
variable, with some making a full recovery and others
unfortunately succumbing to their disease. Various
methods were used for treatment, with high-dose ste-
roids being a unifying treatment choice.
The pathophysiology has been explored in SLE cases
of idiopathic intracranial hypertension (IIH) with diffuse
leukoencephalopathy. There are multiple theories, in-
cluding the possibility of immune-complex mediated
Fig. 1 MRI brain with/without contrast
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damage, autoantibodies interacting (either directly or in-
directly) with antigens on neuronal cell membrane, intra-
thecal cytokine production, and microangiopathy [1, 2].
Various autoantibodies found in relation to increased inci-
dence of NPSLE include anti-phospholipid antibodies,
anti-ribosomal P antibodies, and microtubule-associated
protein-2 antibodies. These autoantibodies theoretically
target endothelial cells, prostacyclins, protein C-S com-
plex, and platelets, leading to acute impact on coagulation
and chronic proliferative vasculopathy [2]. Cranial MRI is
currently the anatomic imaging modality of choice for
these patients, and displays high sensitivity but low specifi-
city for NPSLE. Most NPSLE patients (40–80%) show
small punctate focal lesions in periventricular and subcor-
tical white matter areas on imaging, not necessarily associ-
ated with diffuse brain edema as was the case with our
patient, and cerebral angiography typically is normal [2].
A vast array of findings in the literature make it very diffi-
cult to determine exact pathophysiology of diffuse
leukoencephalopathy with associated cerebral edema.
Pathophysiology is likely multifactorial, involving autoanti-
body reactivity as well as an underlying propensity for
cerebral damage.
Interestingly, our patient is also unique in that she was
diagnosed with SLE but had a negative ANA test noted
on two occasions during her hospitalization and again
after discharge. Additionally, she had a positive dsDNA
antibody, multiple antibodies to extractable nuclear anti-
gens (ENA) and low complements (Table 2). When con-
sidering our patient’s infectious workup, this was possibly
representative of a diffuse polyclonal B-cell response and
cross-reactivity resulting in false positive mycoplasma,
EBV, CMV and the abnormal fluorescent for California
virus, western and eastern equine viruses, and St. Louis
virus antibodies. Additional autoantibody testing was not
pursued until a thorough infectious, metabolic and neuro-
logic workup was negative or inconclusive. Upon discus-
sion with our metabolic team, her lab workup and
imaging did not support a primary metabolic disorder.
Her MR spectroscopy did comment on “elevation of the
glutamine/glutamate complex in short echo MRS in both
the left frontal lobe and right basal ganglia” (which can be
seen with urea cycle disorders but typically in the more
subacute/acute phase). However, her glutamine, citrulline
and arginine were normal on serum amino acids, and
urine orotic acid was normal, which does not support a
urea cycle disorder. L 2 hydroxyglutaric aciduria was
noted to be highly unlikely in the context of normal urine
organic acids and normal lysine on serum amino acids.
Mitochondrial disorders were less likely due to normal
lactate and normal alanine on serum amino acids. Possible
hereditary leukodystrophies were considered, however
without cognitive decline, motor deterioration, dysmorph-
ism, hepatosplenomegaly, or abnormal tone this was
considered less likely. APOPT1 gene (associated with cavi-
tating leukoencephalopathy with cytochrome C oxidase
deficiency) testing was sent and was negative/unremark-
able. Whole exome sequencing did not identify any vari-
ants that could be interpreted to definitively explain her
reported phenotype, decreasing the possibility of a heredi-
tary leukoencephalopathy or underlying genetic defect.
Neurology followed her case closely. Due to significant
cerebral swelling on imaging and tonsillar ectopia, they
did not feel it was safe to do a lumbar puncture due to
risk of herniation. Autoimmune encephalitis was a con-
sideration in both neurology and rheumatology differen-
tial diagnosis. However, her neurologic exam remained
normal, she was without seizure-like activity or behav-
ioral changes, her EEG was without epileptiform dis-
charges, and her imaging was notable for diffuse cerebral
edema with leukoencephalopathy as opposed to imaging
changes limited to the hippocampi (as seen in anti-α-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
(AMPA) antibodies) or limbic system (as seen in anti-
voltage-gated potassium channel (VGKC) antibodies).
She had no evidence of an underlying tumor or malig-
nancy on imaging or lab testing, which can be associated
with autoimmune encephalitis. During her hospital stay,
an autoimmune encephalitis panel in serum was sug-
gested, however her workup continued to return more
convincing for SLE, so this testing was not pursued.
Ultimately, it was the evidence of hypocomplemente-
mia and a highly positive dsDNA antibody that led to
the additional autoantibody testing and ultimately her
diagnosis, though it took an extremely thorough workup
and evaluation by other subspecialties prior to reconsider-
ing SLE as her diagnosis. The dsDNA testing in our la-
boratory is completed by immunofluorescent assay with
Crithidia luciliae, a flagellate parasite containing circula
dsDNA without other nuclear antigens in the kinetoplast
[20]. Crithidia luciliae and Farr assay detect higher-avidity
antibodies, with the greatest specificity for the diagnosis of
SLE [20]. As our testing methods are quite specific, this
prompted pursuing further testing for rheumatologic dis-
ease. She had multiple positive ENA antibodies (Smith,
RNP, SSA, SSB), ribosomal P antibody and neuronal anti-
body on further evaluation (Table 2). Our patient did not
meet classification criteria for SLE based on ACR, SLICC,
or ACR/EULAR. However, her clinical picture, serologies
and response to treatment support the diagnosis of SLE.
Our patient was treated with both Rituximab and
Cyclophosphamide for her SLE. We chose to give Cyclo-
phosphamide given the severity of her CNS involvement
and inflammation with brain edema. Rituximab was also
given because of our patients’ significant auto-antibody
load. B cells have an important role in the pathogenesis
of SLE and lead to significant autoantibody production.
Rituximab effectively helps reduce this level of auto-
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antibodies. As the time to effectiveness for rituximab
and CNS manifestations is unknown, it was important to
treat very aggressively with both Cyclophosphamide and
Rituximab. She responded well to these medications and
was able to discharge home shortly after obtaining im-
munosuppressive therapy.
Our patient is a unique representation of SLE, but her
case may suggest that for some specific instances, where
thorough infectious, metabolic, and neurological testing
are inconclusive, that ANA testing alone may not be suf-
ficient for screening for SLE. There are few descriptions
of such cases in the literature but some do describe the
importance of screening patients with suspected rheu-
matologic disorders with more than just the basic ANA
screen [21]. Testing with other markers specific to SLE
disease activity, e.g. complement levels and anti-dsDNA,
proved critical in the diagnosis of SLE for our patient.
On treatment of her disease over time, her anti-dsDNA
antibody decreased significantly in line with her disease
activity (Table 2), confirming response to treatment.
Various studies propose several reasons as to why some
patients with the diagnosis of SLE have negative ANA
screenings. These include the prozone or hook effect, the
entity of an ANA negative SLE patient, or technical issues
with the ANA screen itself [19]. We believed the prozone
effect may have been responsible for our patient’s negative
ANA result. The prozone effect occurs in cases of very
high antibody concentrations and is thought to be respon-
sible for negative immunoassays that involve the detection
of antigen-antibody complexes [22]. With these assays,
there is dependence on agglutination to reveal the pres-
ence of the antibody and thus confirm a positive test.
With the prozone effect, the antibody concentration is so
high, it interferes with the clumping of antigen-antibody
complexes resulting in a seemingly negative result. ANA
testing was repeated in our patient on multiple occasions
and was consistently reported as negative. The ANA test
at our facility is conducted via immunofluorescence with
HEp-2 cells as the substrate molecule. The American Col-
lege of Rheumatology position statement on ANA testing
states the use of IIF as the gold standard method for ANA
screening, specifically IIF on HEp-2 cells [23]. Her ANA
test being negative initially drew the diagnosis away from
the possibility of SLE, and it ultimately took a very thor-
ough negative workup in other subspecialties before the
diagnosis of SLE was re-considered. If the prozone effect
is the cause of our patient’s negative ANA result, future
ANA tests for our patient could turn positive with treat-
ment of the patient’s disease and reduction in antibody
burden.
Conclusion
Our patient presented with a very rare form of NPSLE,
and in addition was found to be ANA-negative on
serological testing making this a challenging diagnosis of
SLE. Isolated diffuse cerebral edema and leukoencepha-
lopathy in SLE has rarely been reported in the literature.
Resolution is possible with appropriate therapy, but
mortality is a major concern due to the diffuse and se-
vere vasogenic edema with lymphocytic infiltration.
Therefore, it is important to recognize diffuse cerebral
edema with leukoencephalopathy as being on the differ-
ential for possible NPSLE manifestation, despite ANA
results, in order to improve patient outcomes.
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